Skip to main content
KNSA logo

KNSA · Kiniksa Pharmaceuticals International, plc

Track KNSA — free
$93.90 +0.36 (+0.38%) At close · Nov 20
Market Cap
$7.38B
Shares
78.57M
Volume · Nov 20 545.23K Avg daily vol (3M) 658.72K

Price & Indicators

 

Key stats

Close
$93.90
Fri 20 Nov
Open
$93.48
Fri 20 Nov
Average volume, 30 days
827K
shares a session
Short interest
4.3M
5.5% of shares · 3.9 days to cover
Day range
$92.68$95.29
Open $93.48 Close $93.90
52-week closing range
$37.92$98.76
Close $93.90 4.9% under the high
Short volume, last session
59%
Last earnings
Oct 27, 2026
Latest filing
10-Q · Oct 27
Price history
Jan 2020 to Nov 2026

Up next

Feb 23, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 16
Investor event
KPL387 Phase three readout expected in second half of 2027

Kiniksa Pharmaceuticals International, plc expects a KPL387 Phase three readout in the second half of 2027 and guides 2026 revenue to 1.045 to $1.050 billion.

4 source passages
now in our phase three pivotal study with KPL387, which is a monthly IL-1 alpha and beta inhibitor. We'll have readout from our phase three study in the second half of next year. And as Sandra mentioned, with data in the second half of 2027. you guided a 2026 revenue, nicely passing a billion dollar, and then imply the fourth quarter growth. Yeah, maybe just to remind the audience what we've guided to now is 1.045 to $1.050 billion for the full year. Open the document at this passage
Oct 27
Quarterly report 10-Q FY2026 Q3, ended Sep 30
ARCALYST quarterly product revenue rises to $286.0 million

ARCALYST product revenue, net, reached $286.0 million in the quarter ended September 30, 2026, up $105.1 million from $180.9 million, driven mainly by more patients on therapy. Net income for the nine months ended September 30, 2026 was $95.4 million, versus $44.8 million. Quarterly research and development expenses rose to $32.8 million, led by KPL-387 trial costs of $17.3 million.

Revenue $285.97M ▲ 58.1% Net income $47.35M ▲ 156.8% Diluted EPS $0.56 ▲ 143.5%
Read from the MD&A section
5 source passages
We recognized net revenue from the sale of ARCALYST of $286.0 million for the three months ended September 30, 2026, compared to $180.9 million for the three months ended September 30, 2025, an increase of $105.1 million. The increase in product revenue was driven primarily by an increase in patients on therapy. Net income was $95.4 million and $44.8 million for the nine months ended September 30, 2026 and 2025, respectively. Research and development expenses were $32.8 million for the three months ended September 30, 2026, compared to $24.2 million for the three months ended September 30, 2025, an increase of $8.6 million. Direct costs for our KPL-387 program were $17.3 million during the three months ended September 30, 2026, compared to $11.4 million during the three months ended September 30, 2025. Open the document at this passage
Oct 27
Earnings call
ARKLIST third-quarter revenue hits $286 million; 2026 guidance raised

Kinexa reported third-quarter ARKLIST revenue of $286 million, up 58% year over year, and raised its 2026 ARKLIST sales guidance to $1.045 to $1.050 billion. It expects pivotal data for KPL 387 in the second half of 2027 and ended the quarter with $568.8 million in cash.

5 source passages
ARCLIS revenue grew 58% year-over-year to $286 million in the third quarter in addition to our updated 2026 ARKLIST sales guidance of $1.045 to $1.050 billion We announced today that we expect data from this trial in the second half of 2027. The pivotal phase three study with KPL-387 continues to enroll and dose patients. we ended the third quarter with $568.8 million in cash Open the document at this passage
Oct 27
Current report 8-K
ARCALYST Q3 revenue hits $286.0 million; 2026 guidance raised

Kiniksa reported third-quarter 2026 revenue of $286.0 million, up from $180.9 million a year earlier, and net income of $47.3 million versus $18.4 million. It raised its 2026 ARCALYST net product revenue expectation to $1.045 billion to $1.050 billion, from $980 million to $995 million. The company ended September 30, 2026 with $568.8 million in cash, cash equivalents and short-term investments and no debt.

Financial results
4 source passages
Total revenue for the third quarter of 2026 was $286.0 million, compared to $180.9 million for the third quarter of 2025. Kiniksa expects 2026 ARCALYST net product revenue of between $1.045 billion and $1.050 billion, compared to prior guidance of between $980 million and $995 million. Net income for the third quarter of 2026 was $47.3 million, compared to $18.4 million for the third quarter of 2025. As of September 30, 2026, Kiniksa had $568.8 million of cash, cash equivalents, and short-term investments and no debt. Open the document at this passage
Oct 22
Current report 8-K Events of Oct 17
Ross Moat Named President and Chief Operating Officer

Kiniksa appointed Ross Moat as President and Chief Operating Officer, effective immediately, with reporting to Chairman and CEO Sanj K. Patel. Effective January 1, 2027, his annual base salary rises to $700,000 from $650,000 and his annual target bonus to 60% from 55%.

Director or officer change, or executive pay
2 source passages
appointed Ross Moat as President and Chief Operating Officer, effective immediately effective January 1, 2027, the Committee approved increases in Mr. Moat's annual base salary and annual target bonus to $700,000 and 60% from $650,000 and 55%, respectively Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$945.96M
Trailing 12 months
Net income (TTM)
$109.57M
Trailing 12 months
Revenue growth YoY
+58.1%
Year over year
Operating margin
13.8%
Trailing 12 months
P / E (TTM)
71.7
Trailing earnings · reciprocal yield 1.4%
FCF yield
2.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$568.76M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6.1%
Year over year · more shares
Price change (1Y)
+126.3%
Trailing year
Short interest
5.5%
Latest settlement · 3.9 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 27, 2026
Q3 FY26

TL;DR. ARCALYST revenue grew 58% to $286.0 million, full-year guidance was raised to $1.045-$1.050 billion, and penetration, prescribing, profitability, cash generation, digital engagement, and pipeline development advanced. Operating expenses increased, and KPL-387 efficacy remains to be demonstrated in its ongoing Phase 3 trial.

Bullish
  • + ARCALYST Q3 revenue grew approximately 58% year over year to $286.0 million. new
  • + Full-year ARCALYST revenue guidance was raised to $1.045-$1.050 billion from $980-$995 million. new
  • + Operating income rose to $54.2 million and net income increased to $47.3 million from $18.4 million. new
Bearish
  • − R&D expense increased to $32.8 million from $24.2 million, primarily due to increased KPL-387 clinical activity. new
  • − SG&A expense increased to $65.4 million from $49.1 million, primarily due to ARCALYST commercialization investment. new
  • − KPL-387 efficacy remains to be demonstrated in the ongoing Phase 3 pivotal trial. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +47%
above
Price vs 50-day avg +12%
above
RSI (14) 56
neutral
MACD trend Negative
52-week position 92%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +22%
trailing
6-month return +100%
trailing
YTD return +128%
this year
Relative strength +109%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $84 › 200d $64 — 50d above 200d
Institutional flow Accumulating
+14% holders QoQ · +65 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.47% of shares out · ▲ +14.1% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
306 holders — near 2-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Strong
Revenue growth +60%
Y/Y
EPS growth +225%
Y/Y
Free cash flow $136.4M
Valuation P/E 71.7
rich
Quant / Vol
risk profile
Very High
Volatility 56%
annualized · 1-yr
Max drawdown −21%
past year
ATR 4.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 27, 2026
R&D expenses · 2026 $160M – $170M
SG&A expenses · 2026 $270M – $280M
Previous outlook earlier release · from the Earnings Call filed Jul 28, 2026

Still-open targets the latest release did not restate under the same label.

Full year 2026 revenue guidance · full year 2026 $980M – $995M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+47% Bullish
Price vs 50-day avg
+12% Bullish
RSI (14)
56 Neutral
MACD trend
Negative Bearish
52-week position
92% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $84 › 200d $64 — 50d above 200d
Institutional flow Accumulating
+14% holders QoQ · +65 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.47% of shares out · ▲ +14.1% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
306 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $38 Now $94 · 92% Range high $99
vs 200-day avg +47% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KNSA
Kiniksa Pharmaceuticals International, plc
this stock
$7.38B +127.6% +60.1% 71.7 5.5%
TAK
Takeda Pharmaceutical Co Ltd
$69.55B +39.6% — — 0.1%
GALDY
Galderma Group AG
$50.29B +4.1% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$45.77B +25.7% +4.3% 89.2 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
306
% held
60.3%
Net QoQ
+425.6K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
75
View
Short & Settlement
Short Interest Rising
Shares short
4.3M
Days to cover
3.9d
Change
+531.1K sh
View
Short Volume
Short vol %
59%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
51.6K
Value
$4.9M
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
48.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$677.6M
Net income (FY)
$59.0M
EPS diluted
$0.75
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 16, 2026
This year
22

Kiniksa Pharmaceuticals International, plc expects a KPL387 Phase three readout in the second half of 2027 and guides 2026 revenue to 1.045 to $1.050 billion.

View
Proposed Sales
Value
$3.4M
Shares
36.8K
Filed
Nov 2, 2026
View
Exempt Offerings
Offering
$8.8M
Filed
Nov 23, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Kiniksa Pharmaceuticals to Presen…
Published
Nov 11, 2026
View

Performance

5D 20D 120D MTD YTD
KNSA -2.5% +22.4% +100.1% +1.8% +127.6%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +6.0% +31.6% +109.3% +10.5% +126.5%
Key facts CIK 1730430 CUSIP G52694109 13F (30d) 280 filings 272 filers Visit website Investor relations